A5000234147- Biosimilars and Bioanalytical Methods
- RNA modifications and cancer
- Monoclonal and Polyclonal Antibodies Research
- Cancer Immunotherapy and Biomarkers
- Cancer, Lipids, and Metabolism
- Ferroptosis and cancer prognosis
- HER2/EGFR in Cancer Research
- Diabetes Treatment and Management
- Cancer Mechanisms and Therapy
- Metabolism, Diabetes, and Cancer
- Esophageal Cancer Research and Treatment
- Pharmacological Effects of Natural Compounds
- Diabetes Management and Research
- Grief, Bereavement, and Mental Health
- Ovarian cancer diagnosis and treatment
- Tissue Engineering and Regenerative Medicine
- Pharmaceutical studies and practices
- Toxin Mechanisms and Immunotoxins
- Cancer-related molecular mechanisms research
- Pharmacology and Obesity Treatment
- Wound Healing and Treatments
- Cancer, Stress, Anesthesia, and Immune Response
- Mesenchymal stem cell research
- Mycobacterium research and diagnosis
- Health Systems, Economic Evaluations, Quality of Life
First Affiliated Hospital of Guangdong Pharmaceutical University
2022-2024
Central South University
2011-2023
Second Xiangya Hospital of Central South University
2011-2023
Purpose: This study provides a reference for healthcare organizations in the selection and rational use of glucagon-like peptide-1 receptor agonists (GLP-1RAs), based on Rapid Guide Drug Evaluation Selection Chinese Medical Institutions (Second Edition). Methods: According to Edition) released 2023, relevant databases such as PubMed, Cochrane, Embase, drug labels, clinical guidelines were searched information. We systematically evaluated 7 GLP-1RAs marketed China safety, efficacy, economy,...
The national Comprehensive Cancer Network has suggested pembrolizumab as a second-line therapy for esophageal squamous cell carcinoma (ESCC) patients with programmed death ligand-1 (PD-L1) combined positive score (CPS) ≥ 10. However, despite the increased survival rate associated in these patient population, high cost of may influence its antitumor effect. This study aimed to evaluate cost-effectiveness compared chemotherapy treatments (EC) based on KEYNOTE-181 trial.A Markov model was...
Background HLX02 is a newly marketed trastuzumab biosimilar in China, but whether its price reflects potential benefit terms of value remains unclear. In addition, the development biosimilars China just beginning, and state encourages health economic evaluation biosimilars.Methods Based on previously published randomized controlled trial data, Markov model was used to perform treatment HER2-positive recurrent or metastatic breast cancer, calculate quality-adjusted life years (QALYs)...